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ABSTRACT Based upon knowledge of the hydrolytic proﬁle of major -lactamases
found in Gram-negative bacteria, we tested the efﬁcacy of the combination of
ceftazidime-avibactam (CAZ-AVI) with aztreonam (ATM) against carbapenem-resistant
enteric bacteria possessing metallo--lactamases (MBLs). Disk diffusion and agar-
based antimicrobial susceptibility testing were initially performed to determine the
in vitro efﬁcacy of a unique combination of CAZ-AVI and ATM against 21 representa-
tive Enterobacteriaceae isolates with a complex molecular background that included
blaIMP, blaNDM, blaOXA-48, blaCTX-M, blaAmpC, and combinations thereof. Time-kill as-
says were conducted, and the in vivo efﬁcacy of this combination was assessed in a
murine neutropenic thigh infection model. By disk diffusion assay, all 21 isolates
were resistant to CAZ-AVI alone, and 19/21 were resistant to ATM. The in vitro activ-
ity of CAZ-AVI in combination with ATM against diverse Enterobacteriaceae possess-
ing MBLs was demonstrated in 17/21 isolates, where the zone of inhibition was 21
mm. All isolates demonstrated a reduction in CAZ-AVI agar dilution MICs with the
addition of ATM. At 2 h, time-kill assays demonstrated a 4-log10-CFU decrease for
all groups that had CAZ-AVI with ATM (8 g/ml) added, compared to the group
treated with CAZ-AVI alone. In the murine neutropenic thigh infection model, an al-
most 4-log10-CFU reduction was noted at 24 h for CAZ-AVI (32 mg/kg every 8 h
[q8h]) plus ATM (32 mg/kg q8h) versus CAZ-AVI (32 mg/kg q8h) alone. The data pre-
sented herein require us to carefully consider this new therapeutic combination to
treat infections caused by MBL-producing Enterobacteriaceae.
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As a consequence of the threat of rising antibiotic resistance, the Infectious DiseasesSociety of America has challenged the pharmaceutical industry to develop novel
antibiotics (the “10  20 Initiative”; http://www.idsociety.org/10x20/). Of particular
importance are carbapenem-resistant strains of bacteria, which are typically resistant to
most or all commonly used therapeutic options and cause high morbidity and mortality
(1). In response, the “antibiotic pipeline” has delivered an important -lactam–-
lactamase inhibitor combination, ceftazidime-avibactam (CAZ-AVI) (2).
Avibactam (AVI) is a novel diazabicyclooctane (DBO) -lactamase inhibitor with in vitro
activity against serine enzymes, such as the class A extended-spectrum -lactamases
(ESBLs) and Klebsiella pneumoniae carbapenemases (KPCs), as well as the class D OXA-48
found in Enterobacteriaceae and the class C cephalosporinases present in enteric bacteria
and Pseudomonas aeruginosa. AVI restores the activity of CAZ against a broad array of
resistance threats, making CAZ-AVI a welcome addition to the antibiotic armamentar-
ium against Gram-negative bacteria. However, CAZ-AVI is not active against strains
bearing class B metallo--lactamases (MBLs) such as NDM, VIM, and IMP. The mono-
bactam antibiotic aztreonam (ATM) remains stable against MBLs but is not a therapeu-
tic option in many cases because it is inactivated by ESBLs, KPCs, and other cepha-
losporinases frequently found in the background of MBL-producing bacteria (2, 3).
Even before widespread clinical use of CAZ-AVI, case reports appeared that de-
scribed resistance to this novel inhibitor combination (4). As a result of these ﬁndings,
we now know that CAZ-AVI MICs may be elevated in the setting of unfavorable genetic
backgrounds that include resistance determinants that control entry and egress of
antibiotics (5). Recent reports have also described clinical isolates bearing KPC-3 that
are resistant to the combination CAZ-AVI as a result of amino acid substitutions in the
 loop. Additionally, MBLs are a worldwide problem, with outbreaks reported in the
United States in numbers that were previously unanticipated (6, 7).
Knowing that ATM is stable against hydrolysis by MBLs, we hypothesized that
addition of ATM to the CAZ-AVI combination would result in enhanced activity by
“protecting” ATM from the “attack” of ESBLs and other cephalosporinases. Therefore (i)
we tested the in vitro activity of the combination of CAZ-AVI plus ATM against 21
carbapenem-resistant, MBL-producing Enterobacteriaceae isolates containing blaNDM
or blaIMP genes and a pan-susceptible control, (ii) we evaluated the in vivo anti-
bacterial efﬁcacy of CAZ-AVI with ATM in a mouse thigh infection model using an
MBL-producing K. pneumoniae strain, and ﬁnally (iii) we report a case of infection
caused by an Enterobacter cloacae strain containing an MBL treated with ATM in
combination with CAZ-AVI. Our ﬁndings encourage further study of CAZ-AVI with ATM
under experimental and clinical circumstances when therapeutic options against MBL-
producing strains are limited.
RESULTS AND DISCUSSION
As established by current and previous molecular testing (8), each of the isolates
possessed an MBL, with the exception of Escherichia coli DH10B, which served as a
negative control. In Table 1, we show that isolates containing an MBL were resistant to
CAZ (21/21 isolates), ATM (19/21 isolates), and CAZ-AVI (21/21 isolates) by disk diffusion
(9). The combination of CAZ-AVI and ATM produced an inhibition zone of 21 mm,
suggesting susceptibility in 17 of the 21 MBL-producing strains that were tested (i.e.,
21 mm is the susceptibility (S) zone diameter for CAZ-AVI alone), with the measured
zones being larger than with CAZ-AVI or ATM alone: 10 to 15 mm larger for 9 isolates
and 4 to 9 mm larger for 5 isolates (Table 1). In 3 cases where an increase in the
inhibition zone was not found with the combination of CAZ-AVI and ATM, there was
already a signiﬁcant zone of susceptibility to ATM observed.
For the agar dilution MIC determinations, we used a series of doubling dilutions of
CAZ-AVI in the ratio that is found in the commercial preparation (Avycaz) intended for
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patient use. This was a deliberate decision as we feel these dilutions reﬂect doses of
CAZ-AVI that patients receive. The commercial preparation is formulated in a 4:1 ratio
(CAZ at 2 g and AVI at 0.5 g/per vial). The values reported for CAZ-AVI in Table 1 reﬂect
the concentration of the CAZ in the 4:1 ratio formulation. For MIC determinations,
where the efﬁcacy of ATM addition was assessed, ATM was kept at a ﬁxed concentra-
tion of 8, 16, 32, or 64 g/ml and CAZ-AVI was added in doubling dilutions. These
concentrations of ATM were chosen as they represent the expected serum concentra-
tions of the monobactam when delivered in 1- and 2-g doses throughout the dosing
interval, particularly the 8- and 16-g/ml doses. Single 30-min intravenous infusions of
1- and 2-g doses of ATM produce peak serum levels immediately after administration
of 54 and 90 g/ml and 3 and 6 g/ml at 8 h (the end of the dosing interval),
respectively (Azactam package insert).
All 21 isolates were resistant to CAZ and CAZ-AVI alone by agar dilution MIC and disk
diffusion assay, and all demonstrated a reduction in CAZ-AVI MICs with the addition of
ATM (Table 1 and Fig. 1) in a dose-dependent fashion. Notably, one K. pneumoniae
isolate and four E. coli isolates demonstrated MIC values that remained at or above the
resistance breakpoint for CAZ-AVI alone (16/4 g/ml) after the addition of ATM.
However, addition of ATM at higher concentrations of 32 and 64 g/ml for all 5 isolates
brought them into the susceptible MIC range for CAZ-AVI alone (susceptibility, 8/4
g/ml) (Table 1). Remarkably, the results presented herein accurately reﬂect the genetic
backgrounds established in these isolates, and as anticipated, the combination of
CAZ-AVI with ATM worked especially well in NDM-producing strains.
The time-kill curves detail the bactericidal activity of the combination of CAZ-AVI
and ATM against the MBL-containing K. pneumoniae 1.41 isolate. ATM at a ﬁxed
concentration of 8 g/ml was added to various sublethal concentrations of CAZ-AVI
ranging from 8 g/ml CAZ plus 2 g/ml AVI down to 1 g/ml CAZ plus 0.25 g/ml AVI;
corresponding to 4 different MIC multiples of the CAZ-AVI plus ATM agar MIC of 1
g/ml. Time-kill kinetics showed a time-dependent decrease in CFU/ml from 1 to 24 h
(Fig. 2). A 4-log10-CFU decrease was observed by 2 h for all combination concentra-
tions, and by 6 h, approximately 5-log10 reductions were observed, compared to the
growth control, to which antibiotics were not added. After 24 h, there was minimal
regrowth observed for all combinations, still keeping a 3-log10 decrease compared to
FIG 1 ATM placed directly on the CAZ-AVI disk to evaluate synergy. E. cloacae isolate 6.31 was used in
this assay.
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time zero, with the exception of the 8 the MIC, which showed approximately a 6-log10
decrease.
We next evaluated the in vivo antibacterial efﬁcacy of CAZ-AVI in combination with
ATM in a mouse thigh infection model using the MBL-producing K. pneumoniae 1.41
isolate. The results are presented in Table 2 and Fig. 3. Both CAZ alone (256 mg/kg) and
CAZ-AVI alone (256/64 and 128/32 mg/kg) resulted in 3.1-, 4.7-, and 3.7-log-CFU
reductions, respectively, compared to the untreated control group at 24 h. The lower
dose of either CAZ or CAZ-AVI was less effective. ATM alone at doses from 64 to 256
mg/kg every 8 h (q8h) exhibited minimal efﬁcacy (a 1.16- to 1.99-log-CFU reduction).
Our data in Table 2 show that in this model, the addition of ATM to the CAZ-AVI
treatment regimen results in signiﬁcant enhancement in the reduction of infection as
measured by titer in CFU per thigh compared to either agent alone and the untreated
controls. Doses of 32/8 mg/kg q8h CAZ-AVI (4:1 ratio) plus 32 mg/kg q8h ATM reduced
bacterial thigh titers by 3.95 log CFU below that in the 24-h no-antibiotic controls (P 
FIG 2 Time-kill curve for K. pneumoniae isolate 1.41. ATM concentrations were held constant at 8 g/ml for
all combinations, with two exceptions: (i) the growth control (no antibiotics added) and (ii) CAZ-AVI with
no ATM at 8 the MIC. Various ceftazidime-avibactam (CAZ-AVI) concentrations were added corresponding
to 1 (1 g/ml CAZ plus 0.25 g/ml AVI), 2 (2 g/ml CAZ plus 0.5 g/ml AVI), 4 (4 g/ml CAZ plus 1
g/ml AVI), and 8 (8 g/ml CAZ plus 2 g/ml AVI) the MIC of the combination CAZ-AVI plus ATM
obtained by agar dilution (1 g/ml). Three replicates were conducted for each of the conditions reported
in the time-kill assay.
TABLE 2 Log10 CFU per thigh counts for various antibiotic–-lactamase inhibitor combinations in the neutropenic thigh infection model
for K. pneumoniae 1.41-infected micea
Treatment
Dose (mg/kg s.c. q8h,
5 mice/treatment)
Mean log10
CFU/thigh  SD
Change from control at 24 h
with no antibiotics (log10 CFU)
Tukey adjusted P value
(treatment vs 24-h control)
24-h infection control NA 8.46 1.15 NA NA
CAZ 256 5.37 1.17 3.08 0.0405
128 6.12 1.34 2.34 0.3152
64 6.35 1.57 2.11 0.4909
ATM 256 7.30 1.47 1.16 0.9912
128 6.46 1.80 1.99 0.5873
64 6.59 2.02 1.86 0.6936
CAZ-AVI 256/64 3.77 0.18 4.68 <0.0001
128/32 4.75 1.00 3.70 0.0042
64/16 6.23 1.93 2.22 0.4018
32/8 8.30 0.88 0.16 0.9999
CAZ-AVI-ATM 32/8/32 4.51 0.42 3.95 0.0016
16/4/16 6.88 1.63 1.58 0.8818
8/2/8 6.57 1.77 1.88 0.6777
4/1/4 8.47 0.85 0.02 0.9999
aInfection was 5 log10 CFU/mouse with 5 mice per treatment group. Boldface indicates a statistically signiﬁcant value. NA, not applicable.
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0.0016), 3.79 log CFU below those of 32/8 mg/kg q8h CAZ-AVI alone (P  0.003; data
not shown), and 2.08 log CFU below 64 mg/kg ATM alone. Dosages of4/1 mg/kg q8h
CAZ-AVI (4:1 ratio) plus 4 mg/kg q8h ATM were unable to reduce the CFU count.
Clinical commentary. A 72-year-old woman without signiﬁcant medical history
fell and sustained a fractured hip on an excursion. She was treated with a total hip
arthroplasty performed in Eastern Europe and returned home within 2 weeks with a
painful, red surgical site. The arthroplasty was removed in the United States, and all
intraoperative cultures grew carbapenem-resistant Enterobacter cloacae susceptible to
colistin, intermediate to tigecycline (FDA breakpoint), and resistant to all other agents
tested, including fosfomycin. PCR and sequencing efforts revealed that the Enterobacter
cloacae isolate possessed blaNDM-1 (Table 1). The culture also contained an ESBL-
producing Klebsiella pneumoniae isolate and Enterococcus faecalis isolate (ampicillin and
vancomycin susceptible). A hip spacer was not placed at this time, knowing further
debridement would be necessary.
By day 4 of colistimethate sodium (colistin), tigecycline, and meropenem treatment,
serum creatinine increased from 0.9 to 2.4 mg/dl. Colistimethate sodium was reduced
to 1.5 mg/kg every 36 h, and meropenem was adjusted for declining renal function. The
patient underwent repeat washout, with cultures again yielding the carbapenem-
resistant E. cloacae and ESBL-producing K. pneumoniae. CAZ-AVI at 1.25 g three times
daily was added to the antibiotic regimen; however, CAZ-AVI was discontinued after 4
days as the carbapenem-resistant Enterobacter cloacae isolate demonstrated in vitro
resistance by disk diffusion (ATM, 30-g disk, 6-mm zone size; CAZ-AVI, 50-g disk,
18-mm zone size). Meropenem was soon discontinued due to lack of evidence of
efﬁcacy. With normalization of serum creatinine, the colistimethate sodium dose was
increased to 2 mg/kg every 12 h.
Qualitative synergy in the E. cloacae isolate was demonstrated in vitro between
CAZ-AVI and ATM. (The inhibition zone of the CAZ-AVI disk was increased from 18 mm
to 28 mm upon addition of ATM [Table 1]). Therefore, the treatment regimen was
FIG 3 Individual and mean counts of log10 CFU per thigh for various antibiotic–-lactamase inhibitor combinations in the
neutropenic thigh infection model for K. pneumoniae 1.41-infected mice, with 5 log10 CFU/mouse and 5 mice per treatment
group. LOQ, limit of quantitation (2.35 log10 CFU/thigh).
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modiﬁed so that the ﬁnal 3 weeks of her 6-week postoperative antibiotic course were
comprised of colistimethate sodium, CAZ-AVI (2.5 g every 8 h), ATM (2 g every 8 h), and
vancomycin. Six months after completion of antibiotics, the patient underwent suc-
cessful ﬁnal reimplantation of a total hip arthroplasty, with extensive inspection and
washout. Six cultures were obtained from acetabular and femoral spaces. All were
negative for the 3 organisms originally isolated.
Concluding remarks. Based upon an understanding of the biochemical mecha-
nisms of action of these three agents, we show that the combination of ATM and
CAZ-AVI is able to help overcome carbapenem and expanded-spectrum cephalosporin
resistance in MBL-producing strains of enteric bacteria. AVI is a very potent -lactamase
inhibitor of class A and C enzymes, and since most strains of Enterobacter spp. possess
class C enzymes and possibly some class A ESBLs, we reasoned that AVI would prevent
the hydrolysis of CAZ and ATM (10). Although AVI cannot restore susceptibility to
MBL-producing strains, ATM is not susceptible to hydrolysis by MBLs. By inhibiting class
A and C -lactamases with AVI and using ATM to “bypass” the class B metallo--
lactamase, susceptibility can be restored, leading to a successful microbiological and
possible clinical outcome. Our clinical observation is supported by evidence from our
in vitro investigations.
An unexpected beneﬁt from using CAZ and ATM may arise by the simultaneous
inhibition of multiple penicillin-binding proteins (PBPs). CAZ has a high afﬁnity for the
penicillin-binding protein 3 (PBP 3) and moderate afﬁnity for the PBP 1a of certain
Gram-negative organisms, such as E. coli and P. aeruginosa. Binding to PBPs results in
spheroplast formation followed by rapid lysis. Furthermore, AVI and developmental
DBO inhibitors can also bind to certain PBPs (11–13). ATM is relatively PBP 3 speciﬁc.
The combination (CAZ-AVI and ATM) may completely affect the “divisome” of Gram-
negative bacteria and have an independent impact on its own. Of note, the use of
“double -lactams” has some precedent in the literature. Overall, the existing data
suggest that the potential beneﬁt of this approach against Gram-negative pathogens
should be explored carefully, especially given the recent availability of novel inhibitors
and -lactams (14).
There are important limitations that must be considered before uniform application
of this promising combination: (i) further animal testing with additional isolates and
pharmacokinetic (PK) studies along with trials in humans are required before full
endorsement by clinicians, and (ii) results from Enterobacteriaceae should not be
extrapolated to nonfermenters without appropriate testing (studies in progress). At
present, clinical experience using this combination against Stenotrophomonas malto-
philia proved to be successful in a single case (15). Finally, the possibility of cumulative
toxicity from “double--lactam” combinations must be considered when administering
this regimen. However, one major advantage of using ATM is its safety proﬁle. ATM is
safe to use in patients with penicillin allergies, can be administered by prolonged or
continuous infusion, and is not associated with nephrotoxicity. The data presented here
require us to carefully consider CAZ-AVI combined with ATM as a “new therapeutic
opportunity” to treat infections caused by MBL-producing strains, while recognizing the
ongoing need for new antibiotics.
MATERIALS AND METHODS
Antimicrobial susceptibility testing. In vitro efﬁcacy of the CAZ-AVI and ATM combination was
performed on 21 previously characterized strains of diverse species of Enterobacteriaceae (8). Suscepti-
bility testing was initially performed by disk diffusion. Disks containing CAZ (30 g) and CAZ-AVI (30/20
g) were obtained from Becton Dickinson (Sparks, MD) and Actavis (Schaumburg, IL), respectively. ATM
(30-g) disks were made by adding 10 l of a 3,000-g/ml stock of ATM (Chem-Impex International, Inc.,
Wood Dale, IL) solution to blank disks. To test the activity of the combination of CAZ-AVI with ATM, 30
g of ATM was placed directly on the CAZ-AVI disk and allowed to dry for 30 min before use. Isolates
were grown overnight in cation-adjusted Mueller-Hinton broth (CAMHB), diluted to a McFarland 0.5
standard, and inoculated to form a lawn on cation-adjusted Mueller-Hinton agar (MHA) plates. Disks
containing CAZ, CAZ-AVI, and ATM were placed onto the plates and then incubated overnight at 37°C.
For CAZ and ATM, zones of inhibition were interpreted according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines (9). For CAZ-AVI, zones of inhibition were interpreted according to
FDA guidelines.
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Agar dilution MICs for CAZ, ATM, CAZ-AVI, CAZ-ATM, and the CAZ-AVI-ATM combination were
determined in triplicate and performed according to the CLSI protocol (9). Isolates were grown overnight
in CAMHB and stamped on MHA plates containing doubling dilutions of CAZ (Sigma Chemical Co., St.
Louis, MO), ATM (Chem-Impex, International, Inc., Wood Dale, IL) and CAZ-AVI (2/0.5 g per vial [Avycaz;
Allergan]) using a Steers replicator that delivered 104 CFU/spot. The effect of adding a ﬁxed concentra-
tion of 8 or 16 g/ml of ATM to CAZ or to CAZ-AVI was also assessed. Plates were incubated for 18 to
20 h at 37°C, and the antibiotic concentration (g/ml) at which bacterial growth was no longer observed
deﬁned the MIC. A minimum of 3 determinations was done for each susceptibility, with the most
frequently observed result reported.
Time-kill assays. Time-kill assays were performed for K. pneumoniae isolate 1.41 as previously
described, with some modiﬁcations (16). Brieﬂy, freshly prepared colonies were resuspended in 5 ml
CAMHB and incubated overnight in a shaking incubator (37°C, 220 rpm). Cultures were then diluted 1:100
and incubated in a shaking incubator until they reached a 0.5 McFarland standard (approximately 108
CFU/ml). A bacterial suspension was prepared in 50-ml conical tubes containing 10 ml CAMHB so that
the starting inoculum was approximately 106 CFU/ml. CAZ-AVI (Avycaz) was added to the prepared
bacterial suspensions so that the ﬁnal concentration was 1, 2, 4, or 8 the agar MIC of the
CAZ-AVI-ATM combination (1 g/ml CAZ–0.25 g/ml AVI to 8 g/ml CAZ–2 g/ml AVI, with ATM held
constant at 8 g/ml). A control consisting of CAZ-AVI alone was diluted in the prepared bacterial
suspension at 8 the MIC, and a growth control without antibiotics was also included. The starting
inoculum was determined from the growth control tube immediately after dilution and was recorded as
the count at time zero. After addition of antibiotics, the starting inoculum was 1 106 to 1 107 CFU/ml.
Tubes were incubated in a shaking incubator (37°C, 180 rpm), and viability counts were performed at 1,
2, 4, 6, and 24 h by removing 200 l of the culture, diluting as appropriate, and plating 100 l on MHA.
Plates were incubated at 37°C for 18 to 20 h, colonies were counted on plates yielding 30 to 300 colonies
per plate, and the results were recorded as the number of CFU per milliliter. Three replicates were
conducted for each of the conditions reported in the time-kill assay.
PCR and sequencing. PCR ampliﬁcation of blaNDM and other bla genes, in isolates not previously
characterized, was achieved using established primers and ampliﬁed with a MJ Research gradient cycler
model PTC 225 using thermocycling conditions adjusted to the primer melting temperatures (8). Positive
controls included well-characterized isolates (in the laboratory of R.A.B.). Amplicons were sequenced at
a commercial sequencing facility (MCLAB, San Francisco, CA). Sequence data were analyzed using
Lasergene 7.2 software (DNAstar, Madison, WI), and sequences were compared with BLAST online
software (http://blast.ncbi.nlm.nih.gov), using the megablast algorithm.
Mouse thigh infection model. For the thigh infection model, female Hsd:ICR (CD-1) mice from
Envigo were rendered neutropenic by intraperitoneal (i.p.) injection of cyclophosphamide (Cytoxan;
Baxter Healthcare, Deerﬁeld, IL) as previously described (17). Five mice per 2 control and 14 treatment
groups were infected by injecting a prepared inoculum of K. pneumoniae 1.41 at an input CFU of 5.01
log10 CFU/mouse into the right hind thigh muscle contained in a volume of 0.1 ml per animal. At 2
h postinfection, animals were administered subcutaneous doses (q8h) of CAZ (ceftazidime hydrate
[Sigma]), CAZ-AVI (AvyCaz), ATM (Azactam for injection [USP]) or CAZ-AVI plus ATM (1:1). All animals were
euthanized 24 h postinfection, and thighs were aseptically removed into chilled PBS, homogenized
(Kinematica Polytron PT2100 tissue homogenizer), 10-fold serially diluted, plated on brain heart infusion
agar plates containing 0.5% activated charcoal, and incubated for the determination of bacterial thigh
titers (CFU).
The animal studies were conducted under IACUC-approved protocol 2014/15-09-A04 (approved on
31 October 2014 and to expire on 30 October 2017).
Statistical analysis. The 24-h log10 CFU counts were compared across all treatment and control
groups using a one-way analysis of variance (ANOVA). Post hoc pairwise comparisons were performed
across all treatment and control groups, and P values were adjusted according to Tukey’s method. All
analysis was performed using GraphPad Prism 6.0 software.
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